Last reviewed · How we verify

NCT04951765

A Phase I Study to Examine the Effects of Low and High-fat Meals on Orally Administered XZP-3287 in Healthy Adult Subjects

Status unknown Phase 1 Last updated 20 July 2021
What this trial tests

Phase 1 trial testing XZP-3287 in Healthy in 24 participants. Status unknown.

Timeline
1 August 2021
Primary endpoint
1 August 2021
1 December 2021

Quick facts

Lead sponsorXuanzhu Biopharmaceutical Co., Ltd.
PhasePhase 1
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposetreatment
Enrollment24
Start date1 August 2021
Primary completion1 August 2021
Estimated completion1 December 2021
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Xuanzhu Biopharmaceutical Co., Ltd. — full company profile →

Who can join

Adults 18 to 65, any sex, with Healthy. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

This study will be a randomized 3-treatment, cross-over study to evaluate the bioavailability of XZP-3287 administered after a high or low-fat meal.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of XZP-3287

Trials testing the same drug.

Other recruiting trials for Healthy

Currently open trials in the same condition.

Other Xuanzhu Biopharmaceutical Co., Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04951765.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing